Complex In Vitro Model Characterization for Context of Use in Toxicologic Pathology: Use Cases by Collaborative Teams of Biologists, Bioengineers, and Pathologists

• Published in: Toxicologic pathology p. 1926233241253811
• Main Authors: Stokar-Regenscheit, Nadine, Bell, Luisa, Berridge, Brian, Rudmann, Daniel, Tagle, Danilo, Hargrove-Grimes, Passley, Schaudien, Dirk, Hahn, Kerstin, Kühnlenz, Julia, Ashton, Randolph S, Tseng, Min, Reichelt, Mike, Laing, Steven T, Kiyota, Tomomi, Chamanza, Ronnie, Sura, Radhakrishna, Tomlinson, Lindsay
• Format: Journal Article
• Language: English
• Published: United States 01.02.2024
• Subjects: organ on a chip; new approach methodologies (NAMs); histological technique; microphysiological systems; digital pathology; in vitro; biomarker
• ISSN: 1533-1601
• DOI: 10.1177/01926233241253811

Complex in vitro models (CIVMs) offer the potential to increase the clinical relevance of preclinical efficacy and toxicity assessments and reduce the reliance on animals in drug development. The European Society of Toxicologic Pathology (ESTP) and Society for Toxicologic Pathology (STP) are collaborating to highlight the role of pathologists in the development and use of CIVM. Pathologists are trained in comparative animal medicine which enhances their understanding of mechanisms of human and animal diseases, thus allowing them to bridge between animal models and humans. This skill set is important for CIVM development, validation, and data interpretation. Ideally, diverse teams of scientists, including engineers, biologists, pathologists, and others, should collaboratively develop and characterize novel CIVM, and collectively assess their precise use cases (context of use). Implementing a morphological CIVM evaluation should be essential in this process. This requires robust histological technique workflows, image analysis techniques, and needs correlation with translational biomarkers. In this review, we demonstrate how such tissue technologies and analytics support the development and use of CIVM for drug efficacy and safety evaluations. We encourage the scientific community to explore similar options for their projects and to engage with health authorities on the use of CIVM in benefit-risk assessment.